PriceTargets.com logo

DermTech - DMTK Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.33
  • Forecasted Upside: 339.81%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.44 As of 09/29/2023 01:00 AM ET
▼ -0.04 (-2.70%)

This chart shows the closing price for DMTK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DermTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMTK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMTK

Analyst Price Target is $6.33
▲ +339.81% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for DermTech in the last 3 months. The average price target is $6.33, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 339.81% upside from the last price of $1.44.

This chart shows the closing price for DMTK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in DermTech. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/7/2023BTIG ResearchLower TargetBuy ➝ Buy$6.00 ➝ $5.00Low
3/29/2023TD CowenLower TargetOutperform$8.00 ➝ $6.00N/A
11/9/2022StephensLower TargetOverweight$16.00 ➝ $5.00Low
11/8/2022BTIG ResearchLower TargetBuy$15.00 ➝ $6.00Low
11/7/2022CowenLower Target$20.00 ➝ $8.00Low
11/7/2022CowenLower Target$20.00 ➝ $8.00Low
11/4/2022Lake Street CapitalLower Target$14.00 ➝ $6.00Low
11/4/2022William BlairDowngradeOutperform ➝ Market PerformLow
8/17/2022OppenheimerLower TargetOutperform$48.00 ➝ $23.00Low
8/15/2022BTIG ResearchLower TargetBuy$19.00 ➝ $15.00Low
8/9/2022Lake Street CapitalLower Target$34.00 ➝ $14.00Low
8/9/2022Craig HallumLower Target$37.00 ➝ $18.00Low
7/18/2022OppenheimerReiterated RatingOutperform$48.00Low
6/14/2022BTIG ResearchLower TargetBuy$38.00 ➝ $19.00High
5/4/2022CowenLower Target$33.00 ➝ $20.00High
4/14/2022BTIG ResearchReiterated RatingBuy$48.00 ➝ $38.00N/A
3/2/2022Lake Street CapitalLower Target$79.00 ➝ $34.00High
3/2/2022Craig HallumLower Target$50.00 ➝ $37.00High
1/7/2022StephensInitiated CoverageOverweight$26.00Medium
11/21/2021BTIG ResearchLower TargetBuy$53.00 ➝ $48.00High
11/10/2021Craig HallumLower TargetBuy ➝ In-Line$70.00 ➝ $50.00High
5/14/2021OppenheimerReiterated RatingBuy$58.00High
5/3/2021BTIG ResearchInitiated CoverageBuy$53.00Medium
3/5/2021Craig HallumBoost TargetBuy$49.00 ➝ $70.00High
3/4/2021OppenheimerReiterated RatingBuy$58.00Medium
2/11/2021Lake Street CapitalBoost TargetBuy$52.00 ➝ $79.00Low
1/21/2021OppenheimerInitiated CoverageOutperform$53.00High
1/20/2021Craig HallumBoost TargetBuy$23.00 ➝ $49.00High
12/14/2020Craig HallumInitiated CoverageBuy$23.00High
10/29/2020William BlairInitiated CoverageOutperformHigh
9/11/2020Brookline Capital ManagementInitiated CoverageBuyHigh
9/10/2020CowenInitiated CoverageOutperform$20.00High
5/1/2020Lake Street CapitalReiterated RatingBuy$24.00High
3/17/2020Lake Street CapitalReiterated RatingBuy$15.00 ➝ $24.00Low
3/11/2020Lake Street CapitalBoost TargetBuy$15.00 ➝ $24.00Medium
12/5/2019Lake Street CapitalInitiated CoverageBuy$15.00High
(Data available from 9/30/2018 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
5/3/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
6/2/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

DermTech logo
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.44
Low: $1.44
High: $1.54

50 Day Range

MA: $2.29
Low: $1.44
High: $3.53

52 Week Range

Now: $1.44
Low: $1.44
High: $6.44

Volume

249,211 shs

Average Volume

226,234 shs

Market Capitalization

$48.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22

Frequently Asked Questions

What sell-side analysts currently cover shares of DermTech?

The following Wall Street research analysts have issued research reports on DermTech in the last twelve months: BTIG Research, Cowen Inc, Cowen Inc., Lake Street Capital, Stephens, TD Cowen, and William Blair.
View the latest analyst ratings for DMTK.

What is the current price target for DermTech?

6 Wall Street analysts have set twelve-month price targets for DermTech in the last year. Their average twelve-month price target is $6.33, suggesting a possible upside of 339.8%. Cowen Inc. has the highest price target set, predicting DMTK will reach $8.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $5.00 for DermTech in the next year.
View the latest price targets for DMTK.

What is the current consensus analyst rating for DermTech?

DermTech currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DMTK.

What other companies compete with DermTech?

Other companies that are similar to DermTech include Personalis, Exagen, TriSalus Life Sciences, Enzo Biochem and Genetron. Learn More about companies similar to DermTech.

How do I contact DermTech's investor relations team?

DermTech's physical mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The company's listed phone number is (858) 450-4222 and its investor relations email address is inves[email protected]. The official website for DermTech is www.dermtech.com. Learn More about contacing DermTech investor relations.